logo

IPHA

Innate Pharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 0
stock price surged significantly
consensus rating "Strong Buy"
Upward Gap

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About IPHA

Innate Pharma S.A.

A company that developing therapeutic antibodies designed to harness the immune system to treat cancer

Biological Technology
09/23/1999
10/17/2019
NASDAQ Stock Exchange
179
12-31
Depository Receipts (Ordinary Shares)
117 Avenue de Luminy, 13009 Marseille, France
--
Founded on September 23, 1999, Innate Pharma S.A. is a biotechnology company dedicated to the discovery, development and commercialization of first-in-class therapeutic antibodies designed to harness the immune system for the treatment of tumor indications with serious unmet medical needs. The company has extensive experience in the research and development of immuno-oncology and is a pioneer in understanding natural killer cell or NK cell biology.

Company Financials

EPS

IPHA has released its 2022 Q2 earnings. EPS was reported at 0.09, versus the expected 0.00, beating expectations. The chart below visualizes how IPHA has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime